Erste Asset Management GmbH Grows Position in CVS Health Corporation $CVS

Erste Asset Management GmbH lifted its holdings in shares of CVS Health Corporation (NYSE:CVS) by 95.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 53,402 shares of the pharmacy operator’s stock after acquiring an additional 26,059 shares during the period. Erste Asset Management GmbH’s holdings in CVS Health were worth $4,273,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Kingsview Wealth Management LLC boosted its holdings in shares of CVS Health by 316.2% during the third quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock worth $7,873,000 after purchasing an additional 79,340 shares during the last quarter. Assetmark Inc. boosted its holdings in shares of CVS Health by 12.5% during the third quarter. Assetmark Inc. now owns 678,558 shares of the pharmacy operator’s stock worth $51,156,000 after purchasing an additional 75,603 shares during the last quarter. Intech Investment Management LLC boosted its holdings in shares of CVS Health by 50.3% during the third quarter. Intech Investment Management LLC now owns 86,564 shares of the pharmacy operator’s stock worth $6,526,000 after purchasing an additional 28,953 shares during the last quarter. Hamlin Capital Management LLC acquired a new stake in shares of CVS Health during the fourth quarter worth $160,844,000. Finally, Cresset Asset Management LLC boosted its holdings in shares of CVS Health by 56.8% during the third quarter. Cresset Asset Management LLC now owns 35,481 shares of the pharmacy operator’s stock worth $2,675,000 after purchasing an additional 12,849 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Trading Down 0.1%

NYSE:CVS opened at $96.97 on Wednesday. The business’s 50-day moving average is $85.19 and its two-hundred day moving average is $80.32. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a 12 month low of $58.50 and a 12 month high of $98.43. The firm has a market capitalization of $123.73 billion, a PE ratio of 42.72, a price-to-earnings-growth ratio of 0.95 and a beta of 0.62.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same period last year, the company posted $2.25 earnings per share. The firm’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Research analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were given a $0.665 dividend. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 annualized dividend and a yield of 2.7%. CVS Health’s dividend payout ratio (DPR) is 117.18%.

Insider Activity

In related news, Director Larry Robbins sold 1,983,538 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the transaction, the director owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,441,551 shares of company stock worth $323,703,977 over the last three months. 0.85% of the stock is currently owned by corporate insiders.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: UBS raised its price target on CVS to $115 from $100 and reiterated a buy rating, signaling confidence that the shares can still move higher. UBS adjusts price target on CVS Health to $115 from $100, maintains buy rating
• Positive Sentiment: The company continues to highlight growth initiatives, including expanded GLP-1 access, new AI and patient-care programs, and a new CFO appointment for its health care delivery business, all of which suggest ongoing investment in operational execution. CVS Health valuation check as GLP-1 access expands and PBM scrutiny intensifies
• Positive Sentiment: CVS also received recognition for technology that improves medication safety and patient care, reinforcing its push to position itself as a broader health services company rather than only a pharmacy chain. CVS Health recognized for technology that improves medication safety and patient care

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Wall Street Zen upgraded CVS Health from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Robert W. Baird raised their price objective on CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. The Goldman Sachs Group lifted their target price on CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a report on Thursday, February 12th. JPMorgan Chase & Co. lifted their target price on CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of CVS Health in a report on Friday, May 8th. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $100.68.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.